| Literature DB >> 32230944 |
Hannah Binks1, Grace E Vincent2, Charlotte Gupta2, Christopher Irwin3, Saman Khalesi4.
Abstract
Many processes are involved in sleep regulation, including the ingestion of nutrients, suggesting a link between diet and sleep. Aside from studies investigating the effects of tryptophan, previous research on sleep and diet has primarily focused on the effects of sleep deprivation or sleep restriction on diet. Furthermore, previous reviews have included subjects with clinically diagnosed sleep-related disorders. The current narrative review aimed to clarify findings on sleep-promoting foods and outline the effects of diet on sleep in otherwise healthy adults. A search was undertaken in August 2019 from the Cochrane, MEDLINE (PubMed), and CINAHL databases using the population, intervention, control, outcome (PICO) method. Eligible studies were classified based on emerging themes and reviewed using narrative synthesis. Four themes emerged: tryptophan consumption and tryptophan depletion, dietary supplements, food items, and macronutrients. High carbohydrate diets, and foods containing tryptophan, melatonin, and phytonutrients (e.g., cherries), were linked to improved sleep outcomes. The authors posit that these effects may be due in part to dietary influences on serotonin and melatonin activity.Entities:
Keywords: adults; dietary supplements; food; nutrients; sleep duration; sleep quality
Mesh:
Year: 2020 PMID: 32230944 PMCID: PMC7230229 DOI: 10.3390/nu12040936
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1A diagram showing the selection process for articles.
The study characteristics and outcomes for the investigations between tryptophan consumption, tryptophan depletion, and sleep.
| Author (Year) | Design; Location | Duration; Age; Participants (m/f) | Intervention/Control | Sleep Measurements | Outcomes |
|---|---|---|---|---|---|
| Bravo (2013) [ | SB, P; Spain | 3 wk; 55–75 y; 35 (9/26) | 30 g tryptophan-enriched cereals | Actigraphy | Increase in actual sleep time, SE and immobile time and decrease in SOL, wake bouts, total activity and fragmentation index for intervention compared with control and habitual diet. |
| Bhatti (1998) [ | RC, DB, CO | 6 dy; 21–53 y; 11 (11/0) | 100% tryptophan-free amino acid drink/control | PSG | Significant reduction in REM latency for both intervention and control compared to baseline. |
| Mohajeri (2015) [ | RC, DB, P; UK | 19 dy; 45–65 y; 59 (0/59) | lumiVida™ (egg-white protein hydrolysate formulation containing ~70 mg tryptophan)/placebo | Subjective (sleep diaries) | Non-significant improvement in sleep quality for intervention compared with control. |
| Voderholzer (1998) [ | RC, DB, CO, P; Germany | 2 × 4 dy; 23–55 y; 12 (6/6) | Low protein diet + one capsule of 0.5 g L-tryptophan (day 3 and 4), tryptophan-free amino acid drink (day 4)/placebo | PSG | Significant increase in amount of wake periods, wake times and REM density for tryptophan depletion compared with baseline. |
| Arnulf (2002) [ | RC, DB, CO, P; France | 3 dy; 18–39 y; 18 (7/11) | 100% tryptophan-free amino acid drink + capsules containing methionine, arginine and cysteine/placebo | PSG | Significant increase in arousal index, REM sleep onset latency and REM density for intervention. |
CO – Crossover; DB – Double blind; P – Placebo; NREM – Non-rapid eye movement; RC – Randomised controlled; REM – Rapid eye movement; SB – Single blinded; SE – Sleep efficiency; SOL – Sleep onset latency; TST – Total sleep time; WASO – Wake after sleep onset.
The study characteristics and outcomes for the investigations between dietary supplements and sleep.
| Author (Year) | Design; Location | Duration; Age; Participants (m/f/t) | Intervention/Control | Sleep Measurement | Outcomes/Results | Notes |
|---|---|---|---|---|---|---|
| Aspy (2018) [ | RC, DB; Australia | 5 dy; 18–40 y; 100 (31/68/1) | B6 (pyridoxine hydrochloride) only (240 mg) OR B complex (range of doses for each B vitamin)/placebo | Subjective (Sleep diary) | Significantly lower sleep quality for B complex compared with B6 only and placebo. | |
| Gholipour Baradari (2017) [ | RC, DB; Iran | 1 m; 31.20 ± 5.42 y; 53 (4/49/0) | Zn gelatin capsule/placebo | Subjective (PSQI) | Significant improvement of global sleep score and subjective sleep quality for intervention compared with placebo. | Intensive care unit nurses, poor sleepers |
| Romain (2017) [ | RC, DB, P; Spain | 16 wk; 30–50 y; 33 (17/16/0) | HolisFiit supplement (blend of polyphenol compounds; 500 mg)/placebo | Subjective (Athens Insomnia Scale) | Significantly reduced awakening during the night for intervention. | Overweight to slightly obese participants (BMI = 25–35 kg/m2) |
| Sarris (2012) [ | RC, DB, P; Australia | 16 wk; 20–50 y; 114 (59/55/0) | Swisse Men’s Ultivite F1W multivitamin or Swisse Women’s Ultivite F1 W multivitamin/placebo | Subjective ratings of sleep-quality | Non-significant increase in SQ | |
| Wouters-Wesseling (2003) [ | RC, DB, P; The Netherlands | 6 mo; ≥ 65 y; 68 (39/29/0) | Liquid nutrition supplement/placebo | Subjective (Nottingham Health Profile) | Improved sleep quality | |
| Wightman (2015) [ | RC, DB, P; UK | 28 dy; 18–25 y; 15 (5/10/0) | Pure trans-resveratrol capsule (500 mg; TransmaxTM by BiotiviaTM)/placebo | Subjective (PSQI) | No significant findings for global sleep quality score or individual sleep domains. | |
| McCarthy (2012) [ | Single arm trial; US | 28 dy; 27.2 ± 1.7 y; 18 (9/9) | Capsule containing Chlorophytum borivilianum and Velvet bean | Subjective | Significant improvements in global sleep quality score and all sleep domains. | |
| Park (2017) [ | RC, DB, P, CO; Japan | 2 × 5 dy; 25.7 y (mean); 9 (4/5/0) | 100ml can containing 600 mg of chlorogenic acid (CGA)/placebo | PSG | Significantly lower SOL for intervention. | |
| Yamatsu (2015) [ | SB, P; Japan | 2 × 1 wk; 36.8 ± 8.9; 16 (7/9/0) | Capsules containing GABA OR AVLE OR combination of GABA and AVLE/placebo | PSG | Decrease in SOL for GABA | Poor sleepers |
| Subjective (PSQI) | Improved subjective SQ for AVLE | |||||
| Kuratsune (2010) [ | RC, DB, P, CO; Japan | 2 × 2 wk; 25–59 yo; 21 (21/0) | Crocetin and dextrin capsule/placebo | Actigraphy | Significantly less wake episodes for intervention compared with placebo | |
| Subjective (St Mary’s Hospital Sleep Questionnaire) | No significant difference in subjective measures. | |||||
| Um (2017) [ | RC, DB, P; South Korea | 7 dy; 20 (13/7/0) | Phlorotannin supplement/placebo | PSG | Significant decrease in WASO, difference for TST | Participants with self-reported sleep disturbances |
| Subjective (PSQI; ESS; Stanford Sleepiness Scale) | Significant decrease in global sleep qual score and daytime functioning for intervention, no difference between groups.Increase in sleep duration. | |||||
| Umigai (2018) [ | RC, DB, CO, P; Japan | 2 × 14 dy; 35–60 y; 24 (14/10/0) | Gardenia Yellow capsule with 7.5mg of crocetin/placebo | PSG | Significantly increased delta power for crocetin compared with placebo. | Participants with mild sleep complaints |
| Subjective (OSA-MA) | Significant improvements for sleepiness upon rising and feeling refreshed | |||||
| Saito (2017) [ | RC, DB, P; Japan | 12 wk; 20–84 y; 94 (45/74/0) | Placebo (scallop) supplemented with zinc and astaxanthin supplements/placebo | Actigraphy | Significant improvement for SOL compared with placebo. | |
| Subjective (PSQI; sleep diary) | Significant improvement for global sleep score but not significantly different from placebo. |
CO – Crossover; DB – Double blind; M/F – Male/Female; ESS – Epworth Sleepiness Scale; OSA-MA - Oguri–Shirakawa–Azumi Sleep Inventory, Middle-age and Aged version; P – Placebo; PSG – Polysomnography; PSQI – Pittsburgh Sleep Quality Index; RC – Randomised controlled; REM – Rapid eye movement; SB – Single blinded; TST – Total sleep time; WASO – Wake after sleep onset.
Study characteristics and outcomes for investigations between food items and sleep.
| Author (Year) | Design; Location | Duration; Age; Participants (M/F/T) | Intervention/C | Sleep Measurement | Outcomes/Results | Notes |
|---|---|---|---|---|---|---|
| Garrido (2013) [ | RC, P, SB, CO | 2 × 5 dy; 20–85 y; 30 (15/15/0) | Combination of four cultivars of Jerte Valley cherries, plus 7.5 g maltodextrin and 1.5 g ascorbic acid, diluted | Actigraphy | Significant increase in actual sleep time and immobility for young, middle-aged and elderly groups for intervention compared to baseline. | Young, middle-aged and elderly participants |
| Saito (2017) [ | RC, DB, P; Japan | 12 wk; 20–84 y; 94 (45/74/0) | Zinc-rich food (oysters) OR Zinc- and astaxanthin-rich food (oysters and krill)/placebo | Actigraphy | No significant difference in TST. | |
| Subjective (PSQI) | Significant improvement for sleep scores for all groups, not significantly different from placebo. | |||||
| Garrido (2010) [ | CO; Spain | 7 × 3 dy; 35–85 y; 12 | Seven cultivars of Jerte Valley cherries 1 | Actigraphy | Significant increase in actual sleep time for six cultivars in middle-aged group. | Middle-aged and elderly participants |
| Howatson (2011) [ | RC, DB, P, CO; UK | 7 dy; 18–40 y; 20 (10/10/0) | Tart Montmorency cherry juice (Prunus cerasus) concentrate/placebo | Actigraphy | Significantly greater time in bed, TST and SE total for intervention compared with placebo and baseline. | |
| Subjective (Sleep diaries) | Significantly less napping time for intervention |
1 Cherries cultivated in Jerte Valley, Spain, which contain varied levels of serotonin and melatonin. CO – Crossover; DB – Double blind; M/F/T – Male/Female/Trans; P – Placebo; RC – Randomised controlled; PSQI – Pittsburgh Sleep Quality Index; SB – Single Blind SE – Sleep efficiency; SOL – Sleep onset latency; TST – Total sleep time; WASO – Wake after sleep onset.
The study characteristics and outcomes for the investigations between macronutrients and sleep.
| Author (Year) | Design; Location | Duration; Age; Participants (M/F) | Intervention/Control | Sleep Measurements | Outcomes/Results | Notes |
|---|---|---|---|---|---|---|
| Driver (1999) [ | RC; South Africa | 4 dy; 20–24 y; 7 (7/0) | High energy meal (fat 37%, protein 21%, CHO 42%) OR no meal/control | PSG | No significant difference for TST, SOL, TRT or ROL, or spent in each sleep stage. | |
| Subjective (Questionnaire) | No significant difference for subjective sleep quality. | |||||
| Afaghi (2007) [ | RC, CO; Australia | 3 × 1 dy; 18–35 y; 12 (12/0) | High GI meals consumed either 4h or 1h before bedtime/control | PSG | Significant shortening of SOL for high GI meal consumed 4 h before bedtime compared with high GI meal consumed 1 hour before bedtime and low GI meal. | |
| Afaghi (2008) [ | CO; Australia | 5 dy; 18–35 y; 14 (14/0) | Very low CHO, high fat, high protein diet (acute and ketosis phases)/control | PSG | Arousal index significantly increased for NREM N1 and N2 during very low CHO phases. No significant difference for N 3 and N4 or REM. | |
| Lindseth (2011) [ | RC, DB, CO; US | 4 × 4 dy; 19–22 y; 44 | High protein diet OR high fat diet OR high CHO diet/control | Actigraphy | Significantly less wake episodes for high protein diet | |
| Yajima (2014) [ | CO; Japan | 2 dy; 24.6 ± 0.7 y; 10 (10/0) | High CHO meal OR high fat meal | PSG | No significant differences when sleep stages were averaged. | |
| Lindseth (2016) [ | RC, CO; US | 4 × 4 dy; 20.9 ± 1.9; 36 | High protein OR high fat OR high carbohydrate meals/control | Actigraphy | Significantly shorter wake times after consuming high CHO diet. | |
| Subjective (PSQI) | Significantly lower global sleep quality score for high fat diet | |||||
| St Onge (2016) [ | RC, CO; US | 5 dy; 30–45 yo; 26 (13/13) | Ad libitum/control | PSG | No significant difference between conditions for TST, absolute time in N1 and N2, and REM sleep. | |
| Zhou (2016) [ | RC; CO; US | 3 × 4 wk; 14 (3/11) | Energy restricted diets with protein source either beef/pork (BP) or soy/legumes (SL) and either 10% (control), 20% or 30% of intake as protein | Subjective(PSQI) | Improved global sleep quality score for 20% protein intake. | Overweight or obese participants (BMI range 27 to 37.9) |
| Zhou (2016) [ | RC; DB, P; US | 16 wk; 44 (12/32) | High protein energy-restricted diet/control | Subjective (PSQI) | Improvement in global sleep quality score for intervention at week 12 and 16. | Overweight or obese participants |
| Castro (2018) [ | SA - Spain | 4 mo; 18–58 y; 20 (8/12) | High protein diet | Subjective (PSQI; ESS) | Significant improvement in sleepiness mid-intervention (reduced ketosis) | Obese participants (BMI ≥ 30) |
BMI – Body mass index; CHO – Carbohydrate; CO – Crossover; DB – Double blind; ESS – Epworth Sleepiness Scale; M/F – Male/Female; NREM – Non-rapid eye movement P – Placebo; PSG – Polysomnography; PSQI – Pittsburgh Sleep Quality Index; RC – Randomised controlled; REM – Rapid eye movement; SOL – Sleep onset latency; TST – Total sleep time.